The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2024 | An overview of the most promising upcoming treatments for amyloidosis
Saurabh Zanwar, MD, Mayo Clinic, Rochester, MN, discusses upcoming treatments for amyloidosis, highlighting the potential role of venetoclax in combination with daratumumab for patients with the t(11;14) translocation. Additionally, trials of bispecific antibodies are yielding exciting results. Finally, the ongoing Phase III VITAL trial (NCT02312206) of birtamimab (NEOD001) in patients with stage 3B cardiac light chain (AL) amyloidosis has shown an improvement in survival and is currently accruing. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
